Research Network Arizona, Scottsdale, AZ
University of Arizona College of Medicine – Phoenix, AZ
Disclosures
Rationale for Assessment
- Historically, GA with subfoveal involved lesions was considered too advanced to show a meaningful treatment benefit
- This analysis describes:
- ARCHER Phase 2: Vision protection with vonaprument, a C1q inhibitor, versus sham in participants with baseline subfoveal RPE lesions
ARCHER: Phase 2 Trial Of The C1q Inhibitor Vonaprument (ANX007) in Patients with Dry AMD and GA
ARCHER Phase 2:Dose-Dependent Vision Protection Through Month 12
ARCHER Baseline Characteristics Similar in Overall and Subfoveal Populations
ARCHER Phase 2: Dose-Dependent Vision Protection Through Month 12 in Subfoveal Population
ARCHER Phase 2: Vision Protection Through and at Month 12 in Subfoveal Population
ARCHER II Phase 3 Pivotal Program: Well-Informed Design
ARCHER Showed Vision Protection in Participants with Subfoveal Lesions
- Vision protection in the subfoveal population was shown across several key visual acuity measures, including:
- BCVA and LLVA ≥15-letter loss through Month 12
- Mean change from baseline by BCVA and LLVA at Month 12
- ARCHER demonstrated vonaprument vision protection in participants with subfoveal lesions
- The Phase 3 ARCHER II study designed to show vision protection, including in those with subfoveal lesions
- Anticipated communications on track for Month 15 primary endpoint in Q4 2026 and Month 24 primary endpoint in Q3 2027
Thank you
